Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.
Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S, Emerson C, Fidler S, Fisher M, Horne R, Khoo S, Leen C, Mackie N, Marshall N, Monteiro F, Nelson M, Orkin C, Palfreeman A, Pett S, Phillips A, Post F, Pozniak A, Reeves I, Sabin C, Trevelion R, Walsh J, Wilkins E, Williams I, Winston A. Churchill D, et al. Among authors: angus b. HIV Med. 2016 Aug;17 Suppl 4:s2-s104. doi: 10.1111/hiv.12426. HIV Med. 2016. PMID: 27568911 Free article. No abstract available.
British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011.
Nelson M, Dockrell D, Edwards S; BHIVA Guidelines Subcommittee; Angus B, Barton S, Beeching N, Bergin C, Boffito M, Breen R, Cartledge J, Clarke S, Fisher M, Freedman A, Gazzard B, Grant A, Greig J, Jones R, Khoo S, Leen C, Lipman M, Manji H, Miller R, Mitchell S, Ong E, Pozniak A, Schmid M, Shiew M, Singer M, Wilkins E, Williams I, Wood C, Weston R. Nelson M, et al. Among authors: angus b. HIV Med. 2011 Sep;12 Suppl 2:1-140. doi: 10.1111/j.1468-1293.2011.00944_1.x. HIV Med. 2011. PMID: 21851517 Free article. No abstract available.
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.
Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group. Winston A, et al. HIV Med. 2016 Jun;17(6):471-8. doi: 10.1111/hiv.12344. Epub 2015 Nov 26. HIV Med. 2016. PMID: 26611175 Free article.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ, Winston A, Fox J, Orkin C, Herieka EA, Ainsworth JG, Post FA, Wansbrough-Jones M, Kelleher P; Hydroxychloroquine Trial Team. Paton NI, et al. JAMA. 2012 Jul 25;308(4):353-61. doi: 10.1001/jama.2012.6936. JAMA. 2012. PMID: 22820788 Free PMC article. Clinical Trial.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group. Lambert-Niclot S, et al. J Antimicrob Chemother. 2016 Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. J Antimicrob Chemother. 2016. PMID: 26702926 Free article. Clinical Trial.
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
Dickinson L, Gurjar R, Stöhr W, Bonora S, Owen A, D'Avolio A, Cursley A, Molina JM, Fäetkenheuer G, Vandekerckhove L, Di Perri G, Pozniak A, Richert L, Raffi F, Boffito M; NEAT001/ANRS143 Study Group. Dickinson L, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):628-639. doi: 10.1093/jac/dkz479. J Antimicrob Chemother. 2020. PMID: 31754703 Clinical Trial.
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).
Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group. Pett SL, et al. Among authors: angus b. HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x. Epub 2010 Aug 31. HIV Med. 2011. PMID: 20812949 Free PMC article. Clinical Trial.
335 results